Analysts expect that Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) will announce $7.93 million in sales for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Conatus Pharmaceuticals’ earnings. The highest sales estimate is $14.00 million and the lowest is $3.00 million. The company is expected to issue its next earnings results after the market closes on Wednesday, August 2nd.
According to Zacks, analysts expect that Conatus Pharmaceuticals will report full-year sales of $7.93 million for the current fiscal year, with estimates ranging from $16.00 million to $40.09 million. For the next fiscal year, analysts expect that the company will report sales of $47.33 million per share, with estimates ranging from $4.00 million to $107.10 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Conatus Pharmaceuticals.
Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its earnings results on Thursday, May 4th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.20. The business had revenue of $7 million for the quarter, compared to the consensus estimate of $5.88 million. During the same quarter in the prior year, the firm posted ($0.35) earnings per share.
CNAT has been the topic of a number of research analyst reports. Zacks Investment Research cut shares of Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Aegis reaffirmed a “buy” rating and set a $11.00 price target on shares of Conatus Pharmaceuticals in a research report on Friday, May 5th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Conatus Pharmaceuticals in a research report on Thursday, June 29th. Finally, ValuEngine raised shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 24th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Conatus Pharmaceuticals presently has an average rating of “Buy” and an average target price of $13.25.
Several institutional investors have recently added to or reduced their stakes in the company. Eagle Global Advisors LLC bought a new position in Conatus Pharmaceuticals during the second quarter worth about $156,000. Strs Ohio bought a new position in Conatus Pharmaceuticals during the second quarter worth about $153,000. Acadian Asset Management LLC boosted its position in Conatus Pharmaceuticals by 641.1% in the second quarter. Acadian Asset Management LLC now owns 1,097,945 shares of the biotechnology company’s stock worth $6,324,000 after buying an additional 949,785 shares during the period. Russell Investments Group Ltd. bought a new position in Conatus Pharmaceuticals during the second quarter worth about $679,000. Finally, Bank of Montreal Can bought a new position in Conatus Pharmaceuticals during the second quarter worth about $109,000. 22.34% of the stock is currently owned by institutional investors.
Conatus Pharmaceuticals (CNAT) traded down 2.53% on Friday, reaching $5.39. The company’s stock had a trading volume of 401,097 shares. Conatus Pharmaceuticals has a 12 month low of $1.45 and a 12 month high of $9.40. The stock’s 50 day moving average price is $5.79 and its 200 day moving average price is $5.59. The company’s market cap is $157.40 million.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.